Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: A phase I/II study

Oncology

Volumn 67, Issue 3-4, 2004, Pages 257-261

  Cals, L ^a   Nouyrigat, P ^b   Valenza, B ^c   Pedinelli, F J ^d   Juin, P ^e  

^a Centre Hospitalier Fontpré   (France)

^b Clinique du Cap d'Or   (France)

^c Centre Hospitalier de Draguignan   (France)

^d Clinique Rambot Provencale   (France)

^e TIMONE HOSPITAL   (France)

Author keywords

Breast cancer; Docetaxel; Vinorelbine; Weekly regimen

Indexed keywords

DOCETAXEL; METHYLPREDNISOLONE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG SAFETY; EXPERIENCE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HIP PROSTHESIS; HISTOLOGY; HUMAN; INFECTION; LIVER METASTASIS; LUNG METASTASIS; NEUROPATHY; NEUTROPENIA; PERFORMANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTHESIS INFECTION; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 9244259160     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081326     Document Type: Article

References (10)

1. Valero V, Holmes F, Walters R, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-2894.
2. Gasparini G, Caffo O, Barni S, et al: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study. J Clin Oncol 1994;12:2094-2101.
3. Bissery MC, Vrignaud P, Lavelle F: Preclinical profile of docetaxel (taxotere): Efficacy as a single agent and in combination. Semin Oncol 1995;22:3-16.
4. Campone M, Fumoleau P, Delecroix V, et al: Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Ann Oncol 2001;12:909-918.
5. Frasci G, Comella P, D'Aiuto G, et al: Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 2000;11:367-371.
6. Douillard JP, Monnier A, Le Chevalier T, et al: Phase I study of Docetaxel (D) in combination with Vinorelbine (V) in chemotherapy naive patients with advanced non small cell lung cancer (abstract). 8th International Congress on Anti-Cancer Treatment, Paris, 1998, p 81.
7. Leu KM, Kim KM, Larson M, et al: Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer 2001;34:105-113.
8. Miller V: Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer. Semin Oncol 1999;26:12-14.
9. Hainsworth JD, Burris HA, III, Erland JB, et al: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-2168.
10. Briasoulis E, Karavasilis V, Anastasopoulos D, et al: Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999;10:701-706.